OTCPK:PUPP.F

Stock Analysis Report

Executive Summary

Pharmacolog i Uppsala AB (publ), a medical device company, provides solutions for the safe administration of medical drugs in Sweden.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Pharmacolog i Uppsala is not covered by any analysts.

Share Price & News

How has Pharmacolog i Uppsala's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

PUPP.F

0.7%

US Medical Equipment

-0.2%

US Market


1 Year Return

n/a

PUPP.F

9.5%

US Medical Equipment

1.1%

US Market

No trading data on PUPP.F.

No trading data on PUPP.F.


Share holder returns

PUPP.FIndustryMarket
7 Day0%0.7%-0.2%
30 Day0%0.1%2.5%
90 Dayn/a2.5%1.6%
1 Yearn/a10.4%9.5%3.4%1.1%
3 Yearn/a69.3%64.1%45.2%35.8%
5 Yearn/a138.0%110.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is Pharmacolog i Uppsala's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Pharmacolog i Uppsala undervalued based on future cash flows and its price relative to the stock market?

3.32x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Pharmacolog i Uppsala to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Pharmacolog i Uppsala to establish if it is available at substantial discount.


Price Based on Earnings

Pharmacolog i Uppsala is loss making, we can't compare its value to the US Medical Equipment industry average.

Pharmacolog i Uppsala is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Pharmacolog i Uppsala, we can't assess if its growth is good value.


Price Based on Value of Assets

Pharmacolog i Uppsala is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Pharmacolog i Uppsala expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pharmacolog i Uppsala has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Pharmacolog i Uppsala performed over the past 5 years?

-25.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Pharmacolog i Uppsala does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Pharmacolog i Uppsala's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Pharmacolog i Uppsala's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Pharmacolog i Uppsala has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Pharmacolog i Uppsala has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Pharmacolog i Uppsala improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Pharmacolog i Uppsala's financial position?


Financial Position Analysis

Pharmacolog i Uppsala is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Pharmacolog i Uppsala's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Pharmacolog i Uppsala's level of debt (6%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (8.9% vs 6% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 18.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Pharmacolog i Uppsala has sufficient cash runway for more than 3 years based on current free cash flow.

Pharmacolog i Uppsala has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 4% each year.


Next Steps

Dividend

What is Pharmacolog i Uppsala's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Pharmacolog i Uppsala's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Pharmacolog i Uppsala's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Pharmacolog i Uppsala has not reported any payouts.

Unable to verify if Pharmacolog i Uppsala's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Pharmacolog i Uppsala has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Pharmacolog i Uppsala's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average board tenure


CEO

Mats Högberg (55yo)

0yrs

Tenure

0

Mr. Mats Högberg serves as the Chief Executive Officer of Pharmacolog i Uppsala AB (publ) and its Director since 2017. Mr. Högberg served as the Vice President of Sales & Marketing at Pharmacolog i Uppsala ...


Board Age and Tenure

2.7yrs

Average Tenure

The average tenure for the Pharmacolog i Uppsala board of directors is less than 3 years, this suggests a new board.


Insider Trading

More shares have been bought than sold by Pharmacolog i Uppsala individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

Buykr17,82304 Jul 19
Mats Högberg
EntityIndividual
Role
Chief Executive Officer
CEO & Director
Shares15,257
Max Pricekr1.17

Ownership Breakdown


Management Team

  • Hans Dahlin

    Founder

    • Tenure: 9.7yrs
  • Kent Öbrink (54yo)

    Sales & Marketing Manager

    • Tenure: 2yrs
  • Mats Högberg (55yo)

    CEO & Director

    • Tenure: 0yrs

Board Members

  • Erik Hedlund (71yo)

    Chairman of the Board

    • Tenure: 2.6yrs
  • Hans Dahlin

    Founder

    • Tenure: 9.7yrs
  • Olle Johansson

    Director

    • Tenure: 0yrs
  • Mats Högberg (55yo)

    CEO & Director

    • Tenure: 0yrs

Company Information

Pharmacolog i Uppsala AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pharmacolog i Uppsala AB (publ)
  • Ticker: PUPP.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr86.138m
  • Listing Market Cap: kr8.879m
  • Shares outstanding: 9.92m
  • Website: https://www.pharmacolog.com

Location

  • Pharmacolog i Uppsala AB (publ)
  • Ekeby bruk
  • Uppsala
  • Uppsala County
  • 752 75
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PHLOG BOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKJun 2015
PUPP.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJun 2015

Biography

Pharmacolog i Uppsala AB (publ), a medical device company, provides solutions for the safe administration of medical drugs in Sweden. Its lead product is DrugLog, a system used to prevent drug administrati ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 01:26
End of Day Share Price2019/06/25 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.